A potent, selective, brain penetrant and orally active Histamine H3 inverse agonist for the treatment of cognitive dysfunction associated with AD / Schizophrenia. SUVN-G3031 completed all the Pre-clinical, Safety, early Tox and GLP Tox studies. US IND has been approved in Sept-2014. Phase-1 SAD & MAD studies have been completed. SUVN-G3031 demonstrated excellent safety profile and PK with a potential for once a day (OD) treatment is presently undergoing long term toxicity studies prior to initiating Phase 2 study.